CGC

Company Overview — What Does Canopy Growth Corp Do?

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada. Canopy Growth Corp (CGC) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO David E. Klein and employs approximately 3,150 people. With a market capitalization of $412M, CGC is one of the notable companies in the Healthcare sector.

Canopy Growth Corp (CGC) Stock Rating — Avoid (April 2026)

As of April 2026, Canopy Growth Corp receives a Avoid rating with a composite score of 27.6/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.CGC ranks #3,969 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Canopy Growth Corp ranks #684 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CGC Stock Price and 52-Week Range

Canopy Growth Corp (CGC) currently trades at $1.06. The stock lost $0.03 (2.8%) in the most recent trading session. The 52-week high for CGC is $2.38, which means the stock is currently trading -55.5% from its annual peak. The 52-week low is $0.77, putting the stock 37.7% above its annual trough. Recent trading volume was 11.0M shares, indicating strong institutional interest and high liquidity.

Is CGC Overvalued or Undervalued? — Valuation Analysis

Canopy Growth Corp (CGC) carries a value factor score of 25/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.55x, versus the sector average of 2.75x. The price-to-sales ratio is 1.46x, compared to 1.66x for the average Healthcare stock.

At current multiples, Canopy Growth Corp trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Canopy Growth Corp Profitability — ROE, Margins, and Quality Score

Canopy Growth Corp (CGC) earns a quality factor score of 23/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -30.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -20.6% versus the sector average of -33.1%.

On a margin basis, Canopy Growth Corp reports gross margins of 29.7%, compared to 71.5% for the sector. The operating margin is -31.0% (sector: -66.1%). Net profit margin stands at -76.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 18.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CGC Debt, Balance Sheet, and Financial Health

Canopy Growth Corp has a debt-to-equity ratio of 46.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.34x, indicating strong short-term liquidity.

CGC has a beta of 1.47, meaning it is more volatile than the broader market — a $10,000 investment in CGC would be expected to move 46.7% more than the S&P 500 on any given day. The stability factor score for Canopy Growth Corp is 22/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Canopy Growth Corp Revenue and Earnings History — Quarterly Trend

In TTM 2026, Canopy Growth Corp reported revenue of $288M and earnings per share (EPS) of $-0.18. Net income for the quarter was $-228M. Gross margin was 29.7%. Operating income came in at $-90M.

In Q3 2026, Canopy Growth Corp reported revenue of $75M and earnings per share (EPS) of $-0.18. Net income for the quarter was $-63M. Gross margin was 28.8%. Revenue grew -0.3% year-over-year compared to Q3 2025. Operating income came in at $-26M.

In Q2 2026, Canopy Growth Corp reported revenue of $67M and earnings per share (EPS) of $-0.01. Net income for the quarter was $-2M. Gross margin was 32.9%. Revenue grew 5.9% year-over-year compared to Q2 2025. Operating income came in at $-17M.

In Q1 2026, Canopy Growth Corp reported revenue of $72M and earnings per share (EPS) of $-0.22. Net income for the quarter was $-42M. Gross margin was 25.0%. Revenue grew 8.9% year-over-year compared to Q1 2025. Operating income came in at $-23M.

Over the past 8 quarters, Canopy Growth Corp has demonstrated a growth trajectory, with revenue expanding from $66M to $288M. Investors analyzing CGC stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CGC Dividend Yield and Income Analysis

Canopy Growth Corp (CGC) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CGC Momentum and Technical Analysis Profile

Canopy Growth Corp (CGC) has a momentum factor score of 29/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 26/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 48/100 reflects moderate short selling activity.

CGC vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Canopy Growth Corp (CGC) ranks #684 out of 838 stocks based on the Blank Capital composite score. This places CGC in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CGC against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CGC vs S&P 500 (SPY) comparison to assess how Canopy Growth Corp stacks up against the broader market across all factor dimensions.

CGC Next Earnings Date

No upcoming earnings date has been announced for Canopy Growth Corp (CGC) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CGC? — Investment Thesis Summary

The quantitative profile for Canopy Growth Corp suggests caution. The quality score of 23/100 flags below-average profitability. The value score of 25/100 indicates premium valuation. Momentum is weak at 29/100, a headwind for near-term performance. High volatility (stability score 22/100) increases portfolio risk.

In summary, Canopy Growth Corp (CGC) earns a Avoid rating with a composite score of 27.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CGC stock.

Related Resources for CGC Investors

Explore more research and tools: CGC vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CGC head-to-head with peers: CGC vs AZN, CGC vs SLGL, CGC vs VMD.